Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 65

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 65
---
 their use of the technology to these uses, and we could incur substantial
expenses to enforce our rights to our licensed technology in the event of misuse. Also, the United States federal government retains certain
rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The
federal government retains a “nonexclusive, nontransferable, irrevocable, paid-up license” for its own benefit. The Bayh-Dole
Act also provides federal agencies with “march-in rights.” March-in rights allow the government, in specified circumstances,
to require the contractor or successors in title to the patent to grant a “nonexclusive, partially exclusive, or exclusive license”
to a “responsible applicant or applicants.” If the patent owner refuses to do so, the government may grant the license itself.
We sometimes collaborate with academic institutions to accelerate our preclinical research or development. While it is generally our policy
to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure
that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own
or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole
Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.

Additionally, we have and
may continue to collaborate with academic institutions to accelerate our preclinical research or development under written agreements
with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution’s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified
timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights
to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party
intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program
and our business and financial condition could suffer.

Further, our future intellectual
property license agreements may impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones,
royalties or other amounts and other obligations. If we fail to comply with our obligations under